First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan
详细信息    查看全文
文摘
Helicobacter pylori eradication in patients with chronic liver diseases (CLDs) and liver cirrhosis is seldom reported. This study aimed to assess the efficacy of 7-day standard triple therapy in patients with CLD including cirrhosis and to investigate the clinical factors influencing the success of eradication. A total of 592 H. pylori-infected patients, who received 7-day standard first-line triple therapy between January 1, 2014, and December 31, 2014, were recruited. Patients were divided into two groups: CLD group (N = 136) and non-CLD group (N = 456). The eradication rates attained by the CLD and non-CLD groups were 86.0% and 84.2%, respectively, in the per-protocol analysis (p = 0.606). The eradication rates of liver cirrhosis and noncirrhosis CLD were 88.5% and 84.3%, respectively (p = 0.783). The adverse events were similar between the two groups (8.8% vs. 9.2%, p = 0.891). Compliance between the two groups was good (99.3% vs. 99.6%, p = 0.670). The univariate analysis showed male sex to be the significant clinical factor in the non-CLD group (p = 0.001) and alcohol consumption to be the significant clinical factor influencing H. pylori eradication rate in patients with CLD (p = 0.022). Alcohol consumption was the only significant factor influencing H. pylori eradication in multivariate analysis (odds ratio = 3.786, p = 0.031). The results of this study suggest that H. pylori eradication rates in patients with CLD may be comparable with non-CLD patients. Alcohol consumption was the significant factor influencing H. pylori eradication in patients with CLD.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700